IQVIA Holdings, Inc.
US provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.
Segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions.
Overview
Strengths
- Asset-light, cash-generative model: capital expenditure takes only 4.2% of revenue and free cash flow was positive in each of the last 5 years.
- Resilient profitability: operating margin stayed between 10% and 15% in each of the last 5 years.
- Shareholder-friendly capital allocation: the share count has shrunk by 3.0% a year over the last three years through buybacks.
Weaknesses
- High leverage: net debt is 3.8x EBITDA, against a median of 1.2x for its Diagnostics & Research peers.
- Our discounted cash flow target price (121.72 USD) is 54% below the current price.
- Tight liquidity: current liabilities exceed current assets (current ratio 0.75).
Key Financial Data